Proposed issue of securities
Announcement Summary
For personal use only
Entity name
BIONOMICS LIMITED
Announcement Type
New announcement
Date of this announcement 5/1/2022
The Proposed issue is:
A placement or other type of issue | ||
Total number of +securities proposed to be issued for a placement or other type of issue | ||
Maximum Number of | ||
ASX +security code | +Security description | +securities to be issued |
BNO | ORDINARY FULLY PAID | 43,794,000 |
Proposed +issue date
5/1/2022
Refer to next page for full details of the announcement
Proposed issue of securities | 1 / 6 |
Proposed issue of securities
Part 1 - Entity and announcement details
For personal use only
1.1 Name of +Entity
BIONOMICS LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
1.2 | Registered Number Type | Registration Number |
ABN | 53075582740 | |
1.3 | ASX issuer code | |
BNO |
- The announcement is New announcement
- Date of this announcement
5/1/2022
1.6 The Proposed issue is:
A placement or other type of issue
Proposed issue of securities | 2 / 6 |
Proposed issue of securities
Part 7 - Details of proposed placement or other issue
only | ||||||
Part 7A - Conditions | ||||||
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other | ||||||
type of issue can proceed on an unconditional basis? | ||||||
Yes | ||||||
use | 7A.1a Conditions | |||||
Approval/Condition | Date for determination | Is the date estimated or | ** Approval | |||
+Security holder approval | 2/12/2021 | actual? | received/condition met? | |||
Actual | ||||||
Yes | ||||||
Comments | ||||||
personal | ||||||
P rt 7B - Issue details | ||||||
Is the proposed security a 'New | Will the proposed issue of this | |||||
class' (+securities in a class that is | +security include an offer of | |||||
not yet quoted or recorded by ASX) | attaching +securities? | |||||
or an 'Existing class' (additional | No | |||||
securities in a class that is already | ||||||
quoted or recorded by ASX)? | ||||||
Existing class | ||||||
Details of +securities proposed to be issued | ||||||
For | ASX +security code and description | |||||
BNO : ORDINARY FULLY PAID | ||||||
Number of +securities proposed to be issued 43,794,000
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
Yes
Proposed issue of securities | 3 / 6 |
Proposed issue of securities
In what currency is the cash consideration being paid?
USD - US Dollar
What is the issue price per +security?
USD 0.06381
AUD equivalent to issue price amount per +security 0.088490
only | FX rate (in format AUD 1.00 / primary | FX rate (in format AUD rate/primary | |||
currency rate): | currency rate) Primary Currency rate | ||||
USD 0.72110000 | |||||
AUD 1.00 | |||||
Will these +securities rank equally in all respects from their issue date with | |||||
the existing issued +securities in that class? | |||||
use | Yes | ||||
Part 7C - Timetable | |||||
personal | 7C.1 Proposed +issue date | ||||
5/1/2022 | |||||
Part 7D - Listing Rule requirements | |||||
7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? | |||||
Yes | |||||
7D.1a Date of meeting or proposed meeting to approve the issue under listing rule 7.1 | |||||
For | 2/12/2021 | ||||
7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue? No
7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? No
7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? No
Proposed issue of securities | 4 / 6 |
Proposed issue of securities
Part 7E - Fees and expenses
7E.1 Will there be a lead manager or broker to the proposed issue?
Yes | ||
only | 7E.1a Who is the lead manager/broker? | |
Evercore Group L.L.C., | ||
William Blair and Company, L.L.C., | ||
7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker? | ||
The fee paid to lead manager disclosed in Q7E.2C below, covers acting as lead manager. | ||
7E.2 Is the proposed issue to be underwritten? | ||
use | Yes | |
7E.2a Who are the underwriter(s)? | ||
Evercore Group L.L.C., | ||
William Blair and Company L.L.C., | ||
Cantor Fitzgerald and Co, | ||
Berenberg Capital Markets L.L.C., | ||
H.C. Wainwright and Co., L.L.C., | ||
personal | 7E.2b What is the extent of the underwriting (ie the amount or proportion of the proposed issue that is | |
underwritten)? | ||
100% | ||
7E.2c What fee, commission or other consideration is payable to them for acting as underwriter(s)? | ||
Underwriting discount and commissions of 7% of the gross proceeds to Bionomics from the sale of securities in the IPO | ||
7E.2d Please provide a summary of the significant events that could lead to the underwriting being terminated. | ||
Refer to Appendix 3B dated 21 December 2021 | ||
7E.3 Is a party referred to in listing rule 10.11 underwriting or sub-underwriting the proposed issue? | ||
No | ||
7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue | ||
Standard Share Registry, Legal and Other External Advisor fees and expenses. | ||
For | ||
Pa t 7F - Further Information
7F.01 The purpose(s) for which the entity is issuing the securities
As stated in the Prospectus, in the section Use of Proceeds.
7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? No
7F.2 Any other information the entity wishes to provide about the proposed issue
N/A
Proposed issue of securities | 5 / 6 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Bionomics Limited published this content on 04 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 January 2022 08:42:56 UTC.